Fine Control of In Vivo Magnetic Hyperthermia Using Iron Oxide Nanoparticles with Different Coatings and Degree of Aggregation

The clinical implementation of magnetic hyperthermia has experienced little progress since the first clinical trial was completed in 2005. Some of the hurdles to overcome are the reliable production of magnetic nanoparticles with controlled properties and the control of the temperature at the target tissue in vivo. Here, forty samples of iron oxide superparamagnetic nanoparticles were prepared by similar methods and thoroughly characterized in terms of size, aggregation degree, and heating response. Selected samples were intratumorally administered in animals with subcutaneous xenografts of human pancreatic cancer. In vivo experiments showed that it is possible to control the rise in temperature by modulating the field intensity during in vivo magnetic hyperthermia protocols. The procedure does not require sophisticated materials and it can be easily implemented by researchers or practitioners working in magnetic hyperthermia therapies.

Automated summary

The clinical implementation of magnetic hyperthermia has been slow due to the challenges in producing magnetic nanoparticles with controlled properties and controlling the temperature at the target tissue. This study successfully prepared iron oxide superparamagnetic nanoparticles and demonstrated that the rise in temperature can be controlled by modulating the field intensity during in vivo magnetic hyperthermia protocols. This simple procedure can be easily implemented by researchers or practitioners working in magnetic hyperthermia therapies.